New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 1, 2013
11:41 EDTGSK, KERXKeryx takeover rumor driven by 'Sierra World Equity Review,' Feuerstein says
Adam Feuerstein of TheStreet.com said on Twitter that the source of a rumor that GlaxoSmithKline (GSK) may be interested in Keryx Biopharmaceuticals (KERX) is the blog "Sierra World Equity Review." Shares of Keryx spiked earlier in the session and are up 64c, or 10%, in late-morning trading. This note corrects an earlier version that misspelled the name of the Tweet's author. Reference Link
News For KERX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 23, 2015
08:08 EDTKERXKeryx appoints John Neylan, MD, as Chief Medical Officer
Keryx Biopharmaceuticals announced the appointment of John Neylan, MD to the newly created position of Chief Medical Officer. In this role, Dr. Neylan will be responsible for oversight of medical affairs, clinical development and pharmacovigilence at Keryx. Dr. Neylan comes to Keryx from Genzyme, where since 2008 he served in the capacity of SVP, Clinical Development, focusing on specialty metabolic diseases.
April 20, 2015
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
April 16, 2015
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
April 15, 2015
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use